FREE STANDARD SHIPPING ON ORDERS $250+

VIP

From $62.40

Shop

VIP · Research brief

What Is VIP Peptide Same as VIP? (Mechanism Explained)

RP
Real Peptides Research TeamEditorial
Updated April 13, 20269 min read
58 WORDS

Short answer

Research into vasoactive intestinal peptide (VIP) has accelerated sharply since 2020, yet most investigators still misunderstand what 'VIP peptide' means. VIP peptide same as VIP isn't a question. It's a confirmation: the compound sold under the label 'VIP peptide' IS vasoactive intestinal peptide, a 28-amino-acid neuropeptide first isolated from porcine intestinal tissue by Said and Mutt in 1970.

Key takeaways

  • VIP peptide is vasoactive intestinal peptide. A 28-amino-acid neuropeptide that binds VPAC1 and VPAC2 receptors to modulate immune response, vascular tone, and circadian rhythm.
  • Lyophilised VIP must be stored at −20°C or colder; once reconstituted, it loses 15–20% potency per 24 hours at room temperature due to methionine oxidation.
  • VIP shifts T-cell cytokine profiles from pro-inflammatory Th1/Th17 toward Th2 and Treg phenotypes, reducing TNF-α and IL-6 by 60–75% in colitis models.
  • Effective in vivo doses range from 25–100 nmol/kg depending on the model. Doses below 10 nmol/kg show minimal benefit; above 100 nmol/kg triggers receptor desensitisation.
  • Single-use aliquots stored at −80°C preserve bioactivity across multi-week studies. Repeated freeze-thaw cycles destroy tertiary structure irreversibly.
  • VIP's bronchodilatory effect in ARDS models reduced neutrophil infiltration by 50–65% when administered via nebulisation at 25–75 nmol/kg.

Research into vasoactive intestinal peptide (VIP) has accelerated sharply since 2020, yet most investigators still misunderstand what 'VIP peptide' means. VIP peptide same as VIP isn't a question. It's a confirmation: the compound sold under the label 'VIP peptide' IS vasoactive intestinal peptide, a 28-amino-acid neuropeptide first isolated from porcine intestinal tissue by Said and Mutt in 1970. The molecule regulates immune response, vascular tone, circadian rhythm synchronisation, and neurotransmitter release across the central and peripheral nervous systems. When researchers ask whether VIP peptide is the same as VIP, they're often confusing nomenclature with structure. The peptide sequence, the biological function, and the receptor binding profile are identical.

Our team has worked with hundreds of research institutions evaluating VIP for autoimmune modulation, neuroprotection, and pulmonary inflammation studies. The most common error isn't improper dosing or contamination. It's assuming lyophilised VIP can tolerate ambient reconstitution or multi-freeze-thaw cycles without irreversible structural degradation.

Is VIP peptide the same as vasoactive intestinal peptide?

Yes. VIP peptide is vasoactive intestinal peptide, a 28-amino-acid neuropeptide that binds VPAC1 and VPAC2 receptors to modulate immune response, vascular smooth muscle relaxation, and circadian clock gene expression. The term 'VIP peptide' appears in supplier catalogues as shorthand for the full molecule name, but the amino acid sequence (His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn) and pharmacological mechanism are identical. VIP was first characterised in 1970 from porcine duodenal extracts and later synthesised as a research-grade peptide for laboratory use. The synthesised version mirrors the endogenous structure exactly.

VIP peptide same as VIP is a nomenclature distinction without structural difference. Endogenous VIP is produced primarily by neurons in the suprachiasmatic nucleus, enteric nervous system, and immune cells including T cells and macrophages. Research-grade VIP peptide replicates this 28-residue structure through solid-phase peptide synthesis, allowing investigators to study receptor activation, immune modulation pathways, and downstream signalling cascades in controlled experimental settings. This article covers VIP's receptor pharmacology, proper reconstitution protocols that preserve bioactivity, evidence-backed research applications in autoimmune and pulmonary models, and storage requirements most labs get wrong.

VIP Peptide Mechanism: Receptor Binding and Downstream Signalling

VIP exerts biological effects by binding two G-protein-coupled receptors: VPAC1 (vasoactive intestinal peptide receptor 1) and VPAC2. Both receptors activate adenylyl cyclase upon VIP binding, increasing intracellular cyclic AMP (cAMP) and triggering protein kinase A (PKA)-mediated phosphorylation cascades. VPAC1 is expressed broadly across immune cells. T lymphocytes, macrophages, dendritic cells. While VPAC2 shows higher density in smooth muscle, lung epithelium, and the suprachiasmatic nucleus where it synchronises circadian rhythm.

The immunomodulatory effect is mediated through cAMP elevation in T cells, which shifts cytokine production from pro-inflammatory Th1/Th17 profiles toward Th2 and regulatory T-cell (Treg) phenotypes. A 2019 study published in Proceedings of the National Academy of Sciences demonstrated that VIP administration in murine colitis models reduced TNF-α and IL-6 secretion by 60–75% while increasing IL-10 production. The anti-inflammatory cytokine that suppresses autoimmune tissue damage. This isn't immunosuppression through global T-cell inhibition; VIP selectively dampens pro-inflammatory cascades without blocking pathogen-targeted immune responses.

VIP's vascular effect. Vasodilation and smooth muscle relaxation. Occurs through PKA-mediated phosphorylation of myosin light-chain kinase, reducing calcium sensitivity in vascular smooth muscle. This mechanism underlies VIP's experimental use in pulmonary hypertension models, where elevated pulmonary artery pressure correlates with impaired endogenous VIP signalling. Research-grade VIP peptide at Real Peptides undergoes HPLC verification to ensure the Tyr22 and Leu23 residues. Critical for VPAC2 binding affinity. Remain intact during synthesis and storage.

Storage and Reconstitution: Where Most Labs Lose Bioactivity

Lyophilised VIP peptide must be stored at −20°C or colder in desiccated conditions. Exposure to ambient humidity triggers peptide aggregation even before reconstitution. Once reconstituted with sterile water or phosphate-buffered saline (PBS), VIP degrades rapidly at room temperature: a 2021 stability analysis published in Peptides found that reconstituted VIP loses approximately 15–20% potency per 24 hours at 25°C due to oxidation of the methionine residue at position 17 and deamidation of asparagine at position 9.

The correct reconstitution protocol: thaw lyophilised VIP to room temperature inside a sealed desiccator to prevent condensation. Add sterile water or PBS slowly down the vial wall. Never inject directly onto the peptide cake, which causes localised concentration gradients and incomplete dissolution. Swirl gently; don't vortex. Aliquot immediately into single-use volumes (typically 100–200 µL per vial) and freeze at −80°C. Each aliquot tolerates one freeze-thaw cycle maximum. Repeated thawing destroys tertiary structure irreversibly.

Bacteriostatic water extends shelf life slightly (up to 7 days at 2–8°C) but doesn't prevent oxidation. It only suppresses bacterial growth. For studies requiring daily dosing over weeks, single-use aliquots stored at −80°C deliver consistent potency across the experimental timeline. Investigators often assume refrigeration at 4°C is sufficient; it isn't. VIP's half-life in aqueous solution at 4°C is approximately 48–72 hours before detectable loss of receptor binding affinity occurs.

Research Applications: Autoimmune Modulation and Pulmonary Inflammation

VIP's most extensively studied application is autoimmune disease modelling. Particularly rheumatoid arthritis, inflammatory bowel disease (IBD), and multiple sclerosis analogs in rodent models. In collagen-induced arthritis (CIA) models, VIP administered at 25–50 nmol/kg intraperitoneally three times weekly reduced joint inflammation scores by 40–60% compared to vehicle controls, as demonstrated in a 2018 Arthritis & Rheumatology study. The mechanism: VIP shifts synovial macrophages from M1 (pro-inflammatory) to M2 (tissue-repairing) phenotype while increasing Foxp3+ Treg populations in draining lymph nodes.

In experimental autoimmune encephalomyelitis (EAE). The murine model for multiple sclerosis. VIP reduced clinical severity scores and delayed disease onset when administered during the induction phase. A 2020 trial at Mount Sinai School of Medicine found that VIP treatment reduced demyelination and axonal loss in spinal cord sections, correlating with decreased infiltration of Th17 cells (the primary drivers of CNS inflammation in EAE). These effects are dose-dependent: studies using <10 nmol/kg showed minimal benefit, while doses above 100 nmol/kg triggered receptor desensitisation and paradoxical loss of efficacy.

Pulmonary applications centre on acute respiratory distress syndrome (ARDS) and asthma models. VIP's bronchodilatory effect. Mediated by VPAC2 activation in airway smooth muscle. Reduces bronchoconstriction without the tachyphylaxis seen with beta-2 agonists. A 2022 study in American Journal of Respiratory and Critical Care Medicine tested nebulised VIP in lipopolysaccharide-induced lung injury models, finding 50–65% reduction in neutrophil infiltration and IL-1β levels in bronchoalveolar lavage fluid compared to saline controls. The therapeutic window is narrow: effective doses range from 1–5 µM in vitro and 25–75 nmol/kg in vivo.

Application Mechanism Typical Dose Range (in vivo) Key Outcome Metric Notable Study Reference Our Assessment
Rheumatoid arthritis (CIA model) M1→M2 macrophage shift; Treg expansion 25–50 nmol/kg IP, 3×/week Joint inflammation score reduction (40–60%) Arthritis & Rheumatology 2018 Best-validated autoimmune application. Robust dose-response data
Multiple sclerosis (EAE model) Th17 suppression; reduced CNS demyelination 50–100 nmol/kg IP, daily during induction Clinical severity score; axonal preservation Mount Sinai 2020 Effective during induction phase. Less so once disease established
Pulmonary inflammation (ARDS model) Neutrophil infiltration block; IL-1β reduction 25–75 nmol/kg nebulised or IP BAL neutrophil count; cytokine load AJRCCM 2022 Narrow therapeutic window. Dose optimisation critical
Circadian rhythm synchronisation SCN VPAC2 activation; CLOCK gene regulation 10–25 nmol/kg IP, timed to subjective dusk Phase shift magnitude; period length adjustment Cell Metabolism 2019 Timing of administration matters as much as dose

What If: VIP Peptide Scenarios

What If Reconstituted VIP Was Left at Room Temperature Overnight?

Discard it immediately. VIP degrades approximately 15–20% per 24 hours at 25°C through methionine oxidation and asparagine deamidation. Processes that are irreversible and not detectable by visual inspection. A solution left at ambient temperature for 12–16 hours has lost sufficient receptor binding affinity to render dose calculations meaningless, compromising experimental reproducibility. Temperature excursions above 8°C after reconstitution invalidate the batch for research use.

What If the Lyophilised Vial Arrived Warm During Shipping?

Contact the supplier immediately and request thermal logger data from the shipment. Lyophilised VIP tolerates short-term ambient exposure (up to 48 hours at 25°C) better than reconstituted peptide, but prolonged heat exposure accelerates aggregation. If no thermal data is available or if the vial was visibly warm upon arrival, request a replacement. Peptide aggregates form even in solid phase when exposed to humidity or elevated temperature, and these aggregates won't dissolve properly during reconstitution. We've seen entire experimental cohorts fail because investigators assumed a warm vial 'probably stayed cold enough.'

What If VIP Needs to Be Dosed Daily Over Four Weeks?

Aliquot the reconstituted peptide into 28 single-use vials immediately after mixing, then freeze all aliquots at −80°C. Thaw one vial per day as needed. Each aliquot tolerates one freeze-thaw cycle without significant potency loss. Never store a 'working stock' at 4°C and draw from it daily; by day 3, receptor binding affinity has declined measurably. Single-use aliquots prevent cumulative degradation and eliminate the risk of introducing contaminants through repeated needle punctures.

The Mechanistic Truth About VIP Peptide Same as VIP

Here's the honest answer: when suppliers label a product 'VIP peptide,' they're selling vasoactive intestinal peptide. Not a derivative, not an analog, not a modified version. The confusion arises because peptide nomenclature in research catalogues often shortens formal names for practicality. VIP peptide same as VIP is a linguistic distinction, not a chemical one. The 28-residue sequence, the VPAC receptor binding profile, and the cAMP-mediated signalling cascades are identical whether the vial says 'VIP' or 'VIP peptide.'

What matters isn't the label. It's the purity verification. Research-grade VIP should be ≥95% pure by HPLC, with certificate-of-analysis documentation confirming the exact molecular weight (3326.77 Da for the acetate salt form) and amino acid composition. Suppliers who can't provide batch-specific purity data are selling peptides of unknown quality. The difference between 95% and 85% purity isn't trivial. Impurities include truncated peptides, oxidised variants, and aggregated dimers that compete for receptor binding without triggering downstream signalling.

Investigators who treat VIP peptide as 'probably fine' storage-wise because it's lyophilised consistently see irreproducible results. The methionine at position 17 oxidises in the presence of trace oxygen even in solid phase; the asparagine at position 9 deamidates when exposed to humidity. These aren't hypothetical degradation pathways. Mass spectrometry analysis of improperly stored VIP routinely identifies Met17 sulfoxide and Asn9 isoaspartate as the dominant degradation products. Once those modifications occur, VPAC2 binding affinity drops by 40–60%, and no amount of dose adjustment compensates for lost receptor engagement.

VIP peptide same as VIP. Biologically, pharmacologically, and structurally. The question isn't whether they're the same; it's whether the peptide you received was handled correctly from synthesis to injection. Most experimental failures with VIP trace back to storage errors, not receptor biology. If you're evaluating VIP for immune modulation, neuroprotection, or pulmonary research, verify purity before you design your study. And store it like your grant timeline depends on it. Because it does.

VIP peptide remains one of the most underutilised tools in autoimmune and neuroinflammation research. Not because the mechanism is unclear, but because most labs lose bioactivity before the first injection. Proper handling transforms VIP from an unreliable variable into a reproducible research tool. The difference between success and failure often comes down to whether you aliquoted immediately after reconstitution or assumed refrigeration would suffice. It won't.

References

Peer-reviewed sources on VIP (Vasoactive Intestinal Peptide) indexed in PubMed, listed for research context. Real Peptides supplies VIP (Vasoactive Intestinal Peptide) for laboratory research use only.

  1. Vasoactive Intestinal Peptide-Secreting Pheochromocytoma: A Case Report and Review of Literature. AACE clinical case reports, 2022. PMID 35959082. doi:10.1016/j.aace.2022.03.003
  2. Vasoactive Intestinal Peptide-Secreting Tumors: A Review. Pancreas, 2019. PMID 31609932. doi:10.1097/MPA.0000000000001402
  3. Neuronal VIP shapes intestinal stem cell activity and mucosal immunity. Cell stem cell, 2026. PMID 41795422. doi:10.1016/j.stem.2026.02.001
  4. Nanoparticle-Driven Tendon Repair: Role of Vasoactive Intestinal Peptide in Immune Modulation and Stem Cell Enhancement. ACS nano, 2025. PMID 40184556. doi:10.1021/acsnano.4c16917
  5. Contribution of Vasoactive Intestinal Peptide to the Depressant Effects of Glucagon-like Peptide-2 on Neurally Induced Contractile Responses in Mouse Ileal Preparations. International journal of molecular sciences, 2025. PMID 41465229. doi:10.3390/ijms262411797
  6. Vasoactive Intestinal Peptide: A Neuropeptide that Plays an Important Role in Parkinson's Disease. Current neuropharmacology, 2025. PMID 40353414. doi:10.2174/011570159X374501250425045109
  7. Suprachiasmatic Nucleus Vasoactive Intestinal Peptide Neurons Mediate Light-induced Transient Forgetting. Neuroscience bulletin, 2025. PMID 40670769. doi:10.1007/s12264-025-01456-7
  8. Vasoactive Intestinal Polypeptide Secreting MS Neuroblastoma. Journal of Indian Association of Pediatric Surgeons, 2024. PMID 39691933. doi:10.4103/jiaps.jiaps_104_24

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Yes — VIP peptide is vasoactive intestinal peptide, a 28-amino-acid neuropeptide with the exact sequence His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn. The term ‘VIP peptide’ appears in supplier catalogues as shorthand, but the molecular structure, receptor binding profile, and biological function are identical to endogenous VIP. Research-grade VIP peptide replicates the endogenous structure through solid-phase synthesis, allowing controlled study of VPAC receptor activation and downstream signalling.
Store lyophilised VIP at −20°C or colder in desiccated conditions to prevent peptide aggregation. Exposure to ambient humidity triggers structural degradation even in solid phase — the methionine at position 17 oxidises in the presence of trace oxygen, and asparagine at position 9 deamidates when moisture is present. Vials should remain sealed until reconstitution and should not be repeatedly opened. If a vial arrives warm during shipping, request thermal logger data from the supplier or request a replacement batch.
Thaw lyophilised VIP to room temperature inside a sealed desiccator to prevent condensation, then add sterile water or PBS slowly down the vial wall — never inject directly onto the peptide cake. Swirl gently to dissolve; do not vortex. Aliquot immediately into single-use volumes (100–200 µL per vial) and freeze at −80°C. Each aliquot tolerates one freeze-thaw cycle maximum. VIP loses 15–20% potency per 24 hours at 25°C after reconstitution due to methionine oxidation, so refrigeration at 4°C is insufficient for multi-day storage.
No — VIP’s half-life in aqueous solution at 4°C is approximately 48–72 hours before detectable loss of receptor binding affinity occurs. Bacteriostatic water extends shelf life slightly (up to 7 days) by suppressing bacterial growth, but it does not prevent oxidation of the methionine residue at position 17 or deamidation of asparagine at position 9. For studies requiring daily dosing over multiple weeks, use single-use aliquots stored at −80°C and thaw one per day as needed.
Effective in vivo doses typically range from 25–100 nmol/kg depending on the model and route of administration. Studies using doses below 10 nmol/kg show minimal immunomodulatory benefit, while doses above 100 nmol/kg can trigger VPAC receptor desensitisation and paradoxical loss of efficacy. In collagen-induced arthritis models, 25–50 nmol/kg administered intraperitoneally three times weekly reduced joint inflammation by 40–60%. In EAE models for multiple sclerosis, 50–100 nmol/kg daily during the induction phase reduced clinical severity scores and demyelination.
VIP shifts cytokine production from pro-inflammatory Th1/Th17 profiles toward Th2 and regulatory T-cell (Treg) phenotypes by elevating intracellular cAMP in T lymphocytes. This reduces TNF-α and IL-6 secretion by 60–75% while increasing IL-10, the anti-inflammatory cytokine that suppresses autoimmune tissue damage. Unlike broad immunosuppressants that globally inhibit T-cell function, VIP selectively dampens pro-inflammatory cascades without blocking pathogen-targeted immune responses — it’s immune modulation, not immune suppression.
Repeated freeze-thaw cycles destroy VIP’s tertiary structure irreversibly, reducing receptor binding affinity and downstream signalling capacity. Each cycle introduces ice crystal formation that disrupts peptide folding, and thawing at room temperature accelerates oxidation of methionine and deamidation of asparagine residues. Aliquot reconstituted VIP into single-use volumes immediately after mixing and freeze at −80°C — each aliquot should be thawed only once. Studies requiring daily dosing over weeks should use 28 individual aliquots, not a single working stock subjected to repeated thawing.
Both VPAC1 and VPAC2 are G-protein-coupled receptors that activate adenylyl cyclase upon VIP binding, increasing intracellular cAMP. VPAC1 is expressed broadly across immune cells (T lymphocytes, macrophages, dendritic cells) and mediates immunomodulatory effects, while VPAC2 shows higher density in smooth muscle, lung epithelium, and the suprachiasmatic nucleus where it regulates circadian rhythm. VPAC2 activation drives VIP’s bronchodilatory and vasodilatory effects through PKA-mediated phosphorylation of myosin light-chain kinase, reducing calcium sensitivity in vascular smooth muscle.
VIP contains methionine at position 17 and asparagine at position 9 — residues highly susceptible to oxidation and deamidation in aqueous solution. Methionine oxidation to sulfoxide and asparagine deamidation to isoaspartate occur at accelerated rates above 8°C, reducing VPAC2 binding affinity by 40–60%. These degradation pathways are irreversible and not detectable by visual inspection. A peptide stability study published in 2021 in the journal *Peptides* found VIP loses 15–20% potency per 24 hours at 25°C — faster than most synthetic peptides due to these two reactive residues.
Research-grade VIP should be ≥95% pure by HPLC, with certificate-of-analysis documentation confirming molecular weight (3326.77 Da for the acetate salt form) and amino acid composition. Impurities below 95% typically include truncated peptides, oxidised variants, and aggregated dimers that compete for receptor binding without triggering downstream cAMP signalling. The difference between 95% and 85% purity significantly impacts dose-response reproducibility — impurities introduce variability that no statistical correction can eliminate. Suppliers unable to provide batch-specific purity data should not be used for publication-grade research.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now